Regional Regulatory Partnership for Malaria Elimination (RRPME)


Welcome to the RRPME platform at APLMA. This page provides a summary introduction to the Partnership. It also serves as a platform to share key information and reports on RRPME activities since early 2016.

National Drug Regulatory Authorities (NDRAs) play a vital role in ensuring the availability of safe, effective and quality medicines and medical devices needed to reach the goal of malaria elimination by 2030. For this reason, APLMA facilitates a Regional Regulatory Partnership for Malaria Elimination (RRPME); a multi-stakeholder group comprising of national regulatory authorities, technical agencies, academia, donors, product development partnerships, as well as policy and advocacy specialists. RRPME acts as an overarching platform that links, coordinates and provides accountability and direction for activities aimed at malarial elimination, taking account of and leveraging existing regulatory networks. The RRPME meetings provide regulators and partner organization with the opportunity to review progress, discuss challenges, set priority actions and announce new commitments. The RRPME aims to introduce regulatory pathways in Asia Pacific for expedited approval of and access to quality drugs and medical devices for malaria elimination. If a strong proof of concept is established for new malaria products, it could then be broadened and integrated into regional and national systems, and could be applied for other life-saving health commodities. The RRPME also aims to share best practices and encourage the roll out of mechanisms to monitor substandard and falsified antimalarial commodities and to reduce the circulation of Oral Artemisinin Monotherapies, and aims to also improve access to quality commodities for all by expanding on existing strategies and developing new ways to engage the private sector for service delivery.

Footer line